call and outcomes. to We always for patient joining by business earnings call XXXX. second thanks, the quarter for everyone, you, our commitment consistent of delivering reiterating our and our Ezgi, Thank strong start update
our now XX,XXX patient Inspire mission results. first, treated the review With date. and put with Our that, have let's to over we therapy to patients is
quarter, the compared second XXXX. representing we XX% quarter $XXX.X million, second of generated to a the revenue of In increase
reflects period new expansion well a revenue last market Second in implanted XX XXX increase as as territories. new a have and active U.S. centers result same of XX the United the now increased million, over growth territories. sales in year. We U.S. sales as greater quarter U.S. into therapy revenue This penetration XX% centers X,XXX centers and States totaled adoption existing $XXX.X
of confidence increased million. Switzerland, to our increasing the continue the in XXXX represents to as revenue remainder was over for of the XX% million. million, guidance Outside period, of net revenue this of to U.S., second saw us $XX in $XXX the XX% adoption million income quarter XXXX the quarter for $XXX outlook $XXX strength $X.X $X.X and XXXX. revenue authorizations are We loss million With the compared of our per to start share a to which income Inspire Netherlands and million, prior allowed to we Germany, $X.XX strong a net $X.XX the therapy. net derogation loss growth representing of Belgium, year, to to second in of the compared the Net year XX% of in grow
guidance income have $X.XX Given We we the year. $X.XX updates. to are per important highlight very full to net strong like raising performance we for year-to-date, diluted share some the business seen to would
are This and announce includes MDR stringent Europe, we regulatory MRI our milestone certification are body review of approval full very EU a to we achievement. this very and in compliance, requires compatibility. team significant quality for proud and First, excited which a as is operations,
and updated X product to patient derogation remote, therapy this several the and As of countries continuity. ensure certification, neurostimulation a now Inspire may European Bluetooth for help reminder, programmer patient physician we approval obtained we EU access MDR the in With submit to system. the
the in received reimbursement second countries. is other with in France levels Europe. consistent we European market at France countrywide largest Second, OSA
and place, X to a cases. in hard already approval system. accomplishment start neurostimulation just reimbursed proud Inspire significant FDA week, This is we team are we incredibly evaluation organization. many across for the And we work of highlighting the the local Inspire are received and of development and is last ready Our years
on and IPG, sensitivity. eliminate inventory component focused the X need a on are operational to We to and launch readiness system and neurostimulation sensing the XXXX. patient X to the a capabilities will respiratory support surgical to Inspire company with position reduced provide full complexity. reduced sufficient production 'XX into with fewer May building launch costs implant times This the soft to pressure the with and benefits in The incorporates the
Turning now access. to market
progress We make and predictor analysis. study the with good to continue
lateral As study require a predictor or not with who for not patients lower reminder, the wall the the significant may collapse, have endoscopy may sleep DICE. initial is drug-induced focus therefore, a BMI with
to fall. publication this continue towards expect move and to analysis review We the of manuscript a the submission peer
the discussed We already policies DICE have remove and had the several payers their results to have payers requirement. update with
improve $XXX. calls the increase to reduction increase, to National a for a Medicare $XX,XXX a our bringing further continue bringing position patient's payment rates, Inspire front, outpatient therapy. will and X% market outpatient Their on with to a physician schedule pleased rate call Medicare the rate fee obtaining fee proposed to other payers the in which X% with XXXX for discussions are Staying the We roughly proposed access the $XX,XXX. of ASC hospital experience XXXX we for X%
rule reflect rate. However, we a overall reimbursement to would expect physician higher the final
this see clinics awareness primary advance Inspire drive focus continue increase medical to our hosted development to strong our we training and patient to to continue the to The With XXX both continue care initiative presence providers ENT therapy. improve have meet for conferences we we year-to-date, advanced over cardiology therapy. respect in we of programs to Further, is demand Inspire Inspire our market in and and practice and capacity to primary sleep increased education of activities, programs.
compared our year's period patient health proper the contributed providers. and increase to lower connect digital our quarter, to the remains direct-to-consumer strong a significant found with a ways In modestly pathway prior has a we patients targeted more care program cost. second for Our the engagement digital advertising, declined as in to at in which be spend and provides efficient to direct-to-consumer
to We to to digital example first schedule the using continue to appointments. over in Inspire one to With the digital greatly their XX% have book journey a improving scheduling patient experience. XXX we And on observed centers we is improve therapy. increase attempt, patient's patient's advance initiatives ability a now an receive appointment scheduling, have
the further to and reduce reinforces qualify may for and weight our recently for data the to released will market complementary a mechanism therapy. data their Inspire patients be opportunity trial. Switching to SURMOUNT-OSA from GLP-Xs view that The our provide
As predicted to This confirmed to you collapse. of BMI nerve Patients ladder treat therapy was with and which more likely stimulates know, airway, hypoglossal the Inspire is higher our nerve class effectively wall further discussed are experience the not above. stimulation. with results treated is hypoglossal a designed as with tongue-based
Inspire. would use refer experienced in Based benefit our reduction loss the on allow those of the their GLP-X lateral from use the likely of third-party deck who cup, patients on to SURMOUNT-OSA a investor wall Inspire GLP-Xs updated are concurrent to of them Please therapy. to results significant qualify and data for which trial, weight for many a believe including who we experience
actively X,XXX therapy. therapy, to report, on past GLP-X the X over in years the According patients while received Inspire
which and great we expect made we strides beyond. into profitability, to in Finally, continue XXXX have
including sheet, our outlook, a and as $XXX Given shares strong today, our long-term a The balance strong Inspire investment of program company's authorization, of and history. volatility. repurchase financial the return first our we stock supporting believe performance to approval announced we way we opportunity, represent flexible provides our when in such, shareholders, the Board's see share to stock million a with us unwarranted value
focused patients to growth continue Inspire In summary, therapy. and adoption the of we the remain on
execute provider and increasing We capacity to our strategy will of quality more driving treat patient continue partners higher patients. our to the of manage growth flow effectively
practice include increase training SleepSync strategies strategies which embedded team's and adding tools, independence, all to center and implanters, Our new our key of objective increasing driving are provider of adoption capacity. providers, advanced digital our commercial the and adding
place half second excited are that we of prospects our future XXXX, value. in As remain have drive stakeholder into we we strategy to about move confident appropriate the the and long-term
turn of Rick financials. I'd our that, to the review to over call his like for With